Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review - Top-Institutions - MDSpire

Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review

By
Guofa Zhao
Guiliang Han
Xiaomei Yang
Youchao Jia
May 11, 2026

Frontiers In Oncology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Oncology
#2

University of Milan

Milan, Lombardy
Key Differentiators
- Oncology
#3

European Institute of Oncology

Milan, Lombardy
Key Differentiators
- Oncology
#4

Memorial Sloan Kettering Cancer Center

New York, New York
Key Differentiators
- Oncology
#5

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

Boston, Massachusetts
Key Differentiators
- Oncology

Original Source(s)

Frontiers In Oncology

Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review

by Guofa Zhao, Guiliang Han, Xiaomei Yang, Youchao Jia
May 11, 2026

Related Content

European Radiology

Surgery confers survival benefit in De Novo metastatic soft tissue sarcoma patients with low Ki67 or low total lesion glycolysis: a combined PET/CT and clinicopathological analysis

by Shaoli Li, Xin Zheng, Menglei Jin, Hui Wang, Rui Bai, Ying Dong
July 10, 2026

The Medicine Maker

This Week’s CGT News: Radiopharmaceutical Boosts CAR T

A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain

July 13, 2026
5 min

Frontiers In Medicine

Training-only ultrasound-specific augmentation for ovarian tumor segmentation across B-mode and contrast-enhanced ultrasound

by Yini Wang, Luyu Hu, Zebin Xue, Qinzi Li, Jingze Li, Xiaoxia Kong
July 13, 2026